Actively Recruiting

Phase Not Applicable
Age: 20Years +
FEMALE
NCT05505357

Omission of Breast Surgery for Breast Cancer Patients With pCR on MRI and Vacuum-assisted Biopsy After NST (OPTIMIST)

Led by Seoul National University Hospital · Updated on 2024-02-28

533

Participants Needed

1

Research Sites

453 weeks

Total Duration

On this page

Sponsors

S

Seoul National University Hospital

Lead Sponsor

M

Ministry of Health & Welfare, Korea

Collaborating Sponsor

AI-Summary

What this Trial Is About

A prospective, multicenter, single-arm non-inferiority trial to demonstrate that breast cancer patients who are predicted to have a pathologic complete response on MRI and vacuum-assisted biopsy after neoadjuvant systemic therapy, and are omitted breast surgery have a non-inferior 5-year disease-free survival compared to those who had received breast surgery.

CONDITIONS

Official Title

Omission of Breast Surgery for Breast Cancer Patients With pCR on MRI and Vacuum-assisted Biopsy After NST (OPTIMIST)

Who Can Participate

Age: 20Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female sex
  • Age 20 years or older
  • No clinical or radiologic distant metastasis
  • Invasive ductal carcinoma tumor type
  • HER2 positive tumor subtype (including luminal B type, triple negative)
  • Initial tumor size 5 cm or less, clinical node status cN0-2
  • Measurable tumor size
  • Expected to achieve pathologic complete response after neoadjuvant chemotherapy (MRI size 1.0 cm or less AND lesion-to-background parenchymal signal enhancement ratio of 1.6 or less)
  • Clip inserted at the primary tumor site before or during neoadjuvant chemotherapy
  • Able to give informed consent and make voluntary decisions
Not Eligible

You will not qualify if you...

  • Two or more tumor lesions (multifocal lesion)
  • Residual microcalcification greater than 2 cm after neoadjuvant chemotherapy
  • Bilateral breast cancer or inflammatory breast cancer
  • Contraindication to radiotherapy
  • History of previous contralateral breast cancer
  • Breast cancer with distant metastasis
  • Allergy to MRI contrast agents
  • Male breast cancer
  • Unable to give informed consent due to poor general condition
  • BRCA mutation carrier
  • Willingness to receive breast surgery
  • History of cancer diagnosis within 5 years (except for non-melanoma skin cancer and ductal carcinoma in situ)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Seoul National University Hospital

Seoul, South Korea

Actively Recruiting

Loading map...

Research Team

H

Han-Byoel Lee

CONTACT

H

Hong-Kyu Kim

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here